WATSON 3209 (Rivastigmine Tartrate 3 mg)
Pill with imprint WATSON 3209 is Yellow, Capsule-shape and has been identified as Rivastigmine Tartrate 3 mg. It is supplied by Watson Pharmaceuticals.
Rivastigmine is used in the treatment of alzheimer's disease; lewy body dementia; parkinson's disease and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 3 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WATSON 3209
Rivastigmine Tartrate
- Imprint:
- WATSON 3209
- Strength:
- 3 mg
- Color:
- Yellow
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Cholinesterase inhibitors
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Watson Pharmaceuticals
- Inactive Ingredients:
- silicon dioxide colloidal
hypromellose
magnesium stearate
microcrystalline cellulose
gelatin
titanium dioxide
ferric oxide yellow
Note: Inactive ingredients may vary.
Other Labelers / Repackagers:
| NDC Code | Labeler / Repackager |
|---|---|
| 63739-0577 | McKesson Packaging Services |
More about rivastigmine
- Rivastigmine Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 21 Reviews
- Drug class: cholinesterase inhibitors
Consumer resources
- Rivastigmine
- Rivastigmine transdermal
- Rivastigmine Capsules
- Rivastigmine Oral Solution
- Rivastigmine Patch
- ... +2 more
Other brands: Exelon
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
